#diabetes management #Switzerland #Insulin Delivery #Horw #CeQur

CeQur Secures $100 Million Series E for Innovative Insulin Delivery Solutions

CeQur, a cutting-edge company focused on transforming insulin delivery for individuals with diabetes, has announced the completion of a $100 million Series E financing round. This significant investment is a testament to the strong confidence investors have in the company’s commercial strategy, clinical outcomes, and the increasing necessity for a simplified method of administering mealtime insulin.

As the diabetes epidemic continues to grow, the need for more manageable and efficient insulin delivery systems has never been more crucial. CeQur aims to address this demand through its innovative product, CeQur Simplicity™, a user-friendly, wearable insulin patch designed to streamline mealtime dosing.

The newly acquired funds will be channelled into various facets of CeQur’s operations, enhancing its capabilities to serve healthcare providers and patients alike. The company plans to expand its field sales team to foster deeper connections with diabetes specialists and primary care physicians, ensuring that more patients are aware of and can access this groundbreaking solution.

Accelerating Growth with New Innovations

The upcoming phase in CeQur’s development includes introducing an extended 7-day wear option for the patch and providing customizable doses of 1-unit and 2-units to accommodate a broader patient demographic. Through these enhancements, CeQur aims to cater to the diverse needs of those affected by diabetes, aiming for improved adherence to prescribed insulin regimens.

Bradley Paddock, President and CEO of CeQur, expressed optimism about the company’s future, stating, _“We have the commercial infrastructure, new clinical evidence, and an exciting pipeline. Now we have the capital to accelerate our growth.”_ This funding round marks an exciting chapter for CeQur as they target to empower diabetic patients and simplify their treatment journey significantly.

Clinical trials indicate that CeQur Simplicity is effectively helping patients adhere better to insulin regimens compared to traditional multiple daily injections. Nearly 90% of users reported improved adherence, with data also showing significantly improved A1C and time-in-range metrics. This overwhelming positive feedback underscores the demand for CeQur’s innovative solutions in diabetes care.

Moreover, with over 85% of insurance claims currently covering CeQur Simplicity as a pharmacy benefit, patients face an average copay of less than $45 per month, making it accessible to a larger audience.

Confidence in Vision and Execution

Mike Rubino, CFO of CeQur, further emphasized the importance of this financing round, remarking, _“This financing is a direct reflection of what the CeQur team has built and the confidence our investors have placed in CeQur's growth trajectory.”_ This investment not only represents user confidence but also reflects a broader shift towards patient-centered diabetes management strategies.

With the FDA issuing new clearances and the availability of compelling clinical data, CeQur Simplicity stands on the cusp of transforming the landscape of insulin delivery. The focus on user comfort, ease of access, and improved health outcomes positions CeQur as a leader in diabetes care solutions.

For patients yearning for alternatives to traditional insulin administration, CeQur continues to develop the technology that can help them maintain better control of their diabetes management without the burden of complex regimens.

In conclusion, with the recent funding, CeQur is set to launch into an ambitious phase of development that promises not just to innovate but also to realign diabetes treatment with patient needs, ultimately driving better health outcomes for all users.

For more information regarding CeQur Simplicity and to explore their offerings, visit MyCeQurSimplicity.com or contact them at 1-888-55-CEQUR.